What is Ionetix?
Ionetix is a specialized company focused on the development and operation of compact superconducting cyclotrons. These advanced particle accelerators are designed for the on-site and distributed production of medical radioisotopes. The company's core business involves supplying diagnostic imaging agents and therapeutic alpha emitters, particularly for cancer treatment. By enabling healthcare providers to produce PET tracers and targeted radiopharmaceuticals locally, Ionetix is advancing precision medicine and improving patient access to critical therapies.
How much funding has Ionetix raised?
Ionetix has raised a total of $31M across 2 funding rounds:
Debt
$1M
Stock/Share Issuance
$30M
Debt (2020): $1M with participation from PPP
Stock/Share Issuance (2026): $30M, investors not publicly disclosed
Key Investors in Ionetix
PPP
Public-Private Partnership
What's next for Ionetix?
The recent major strategic investment signals a new phase of growth and expansion for Ionetix. This capital infusion is expected to accelerate the company's technological advancements, broaden its production capabilities, and potentially expand its market reach. The focus on distributed radioisotope production positions Ionetix to capitalize on the increasing demand for personalized cancer therapies and advanced diagnostic tools, suggesting a trajectory towards scaling its operations and solidifying its position as a key innovator in the radiopharmaceutical industry.
See full Ionetix company page
